| Literature DB >> 24862758 |
Jean-Baptiste Gorin1, Jérémie Ménager1, Sébastien Gouard1, Catherine Maurel1, Yannick Guilloux1, Alain Faivre-Chauvet2, Alfred Morgenstern3, Frank Bruchertseifer3, Michel Chérel4, François Davodeau1, Joëlle Gaschet5.
Abstract
Radioimmunotherapy (RIT) is a therapeutic modality that allows delivering of ionizing radiation directly to targeted cancer cells. Conventional RIT uses β-emitting radioisotopes, but recently, a growing interest has emerged for the clinical development of α particles. α emitters are ideal for killing isolated or small clusters of tumor cells, thanks to their specific characteristics (high linear energy transfer and short path in the tissue), and their effect is less dependent on dose rate, tissue oxygenation, or cell cycle status than γ and X rays. Several studies have been performed to describe α emitter radiobiology and cell death mechanisms induced after α irradiation. But so far, no investigation has been undertaken to analyze the impact of α particles on the immune system, when several studies have shown that external irradiation, using γ and X rays, can foster an antitumor immune response. Therefore, we decided to evaluate the immunogenicity of murine adenocarcinoma MC-38 after bismuth-213 ((213)Bi) irradiation using a vaccination approach. In vivo studies performed in immunocompetent C57Bl/6 mice induced a protective antitumor response that is mediated by tumor-specific T cells. The molecular mechanisms potentially involved in the activation of adaptative immunity were also investigated by in vitro studies. We observed that (213)Bi-treated MC-38 cells release "danger signals" and activate dendritic cells. Our results demonstrate that α irradiation can stimulate adaptive immunity, elicits an efficient antitumor protection, and therefore is an immunogenic cell death inducer, which provides an attractive complement to its direct cytolytic effect on tumor cells.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24862758 PMCID: PMC4094834 DOI: 10.1016/j.neo.2014.04.002
Source DB: PubMed Journal: Neoplasia ISSN: 1476-5586 Impact factor: 5.715